西妥昔单抗联合化疗治疗13例晚期胃癌的临床观察  

Clinical observation of cetuximab plus chemotherapy in the treatment of advanced gastric cancer

作　　者：肖小意[1] 戴广海[1] 孙琼[1] 石燕[1] 吴倩[1] 

机构地区：[1]北京解放军总医院解放军医学院肿瘤综合治疗科,100853

出　　处：《临床肿瘤学杂志》2013年第4期361-363,共3页Chinese Clinical Oncology

摘　　要：目的观察西妥昔单抗联合化疗治疗晚期胃癌的疗效及毒副反应。方法采用西妥昔单抗联合传统化疗药物治疗13例晚期胃癌患者,西妥昔单抗首剂负荷量400mg/m2,之后每周给予维持剂量250mg/m2,并联合常用化疗方案,化疗2～3个周期后评价疗效。结果 13例患者中,一线治疗6例,获PR2例,SD4例;多线治疗7例,获PR1例,SD2例,PD3例,1例疗效无法评价。主要毒副反应为骨髓抑制、胃肠道反应和皮肤黏膜反应。截至2012年12月30日,13例患者中存活2例,死亡11例,生存时间为3.9～40.8个月,中位生存时间(OS)为16.4个月(95%CI:8.4～20.4个月)。结论西妥昔单抗联合化疗治疗国人晚期胃癌可能有较好的疗效与安全性,但需要扩大样本进一步研究。Objective To investigate the efficacy and side effects of cetuximab plus chemotherapy in treatment of advanced gastric cancer. Methods Thirteen patients with advanced gastric cancer were treated with cetuximab plus traditional chemotherapy. Cetuximab 400mg/m2 was taken at the first dose and a maintenance dose was 250mg/m2 every week. The curative effects were evalua- ted after 2-3 cycles. Results Out of the total 13 patients, 6 cases received first-line treatment, 2 with PR, 4 with SD ; seven cases received multi-chemotherapy treatment, 1 with PR, 2 with SD, 3 with PD, and 1 case could not be evaluated. The main toxic reactions were myelosuppression, digestive tract reaction and skin and mucosa reactions. Until the deadline date（ December 30, 2012）, two of the 13 patients survived, and 11 patients died. The survival time ranged from 3.9 to 40. 8 months, and the median survival time was 16. 4 months （95 % CI： 8.4-20. 4）. Conclusion Cetuximab plus chemotherapy in the treatment of advanced gastric cancer may have good efficacy and toxicity can be tolerated.

关 键 词：胃癌 西妥昔单抗 化学治疗 回顾性研究 

分 类 号：R735.2[医药卫生—肿瘤]